Indicated for treatment of bleeding episodes and perioperative management in adults and children with hemophilia A or B with inhibitors, congenital factor VII (FVII) deficiency, Glanzmann’s thrombasthenia with refractoriness to platelet transfusions, and in adults with acquired hemophilia.
Glanzmann’s thrombasthenia with refractoriness to platelet transfusions
Dallas has Glanzmann’s
thrombasthenia
with refractoriness to
platelet transfusions.
NovoSeven® can manage bleeding symptoms in hospitals and at home, offering bleed control and management for patients with Glanzmann's thrombasthenia (GT) with refractoriness to platelet transfusions, with or without antibodies to platelets.1,2
NovoSeven® RT (coagulation Factor VIIa, recombinant) does not just address symptoms—it controls bleeds at the source1
Effective management of GT with refractoriness to platelet transfusions may require more than supportive care, as it can pose a risk of severe, ongoing, and potentially life-threatening bleeding episodes. NovoSeven® RT is the only FDA-approved therapy for treatment of bleeding episodes and perioperative management for adults and children with GT with refractoriness to platelet transfusions, working directly at the bleed site for bleed control and without depending on platelet response.1
Bleed control in GT with refractoriness to platelet transfusions
in all bleeding episodes1,a
(266 bleeding events)
in all surgical procedures1,a
(160 surgical procedures)
aAdjudicator-assessed effectiveness of treatment regimens in patients with GT (N=218) in all severe bleeding episodes and all surgical procedures (N=1073) based on review of Glanzmann’s Thrombasthenia Registry (GTR) data unblinded to investigator-coded efficacy. Efficacy was evaluated on a 2-point scale (clinical assessment of success or failure of treatment regimen as a whole, blinded and unblinded to investigator-coded outcome) including 92 patients treated with NovoSeven® RT for 266 bleeding episodes and 77 patients treated for 160 surgical procedures.1
GT=Glanzmann's thrombasthenia.
Established safety profile
Thrombotic events in <0.2% of bleeding episodes in GT based on clinical trial data, patient registry data, and other safety data1
Serious arterial and venous thrombotic events have been reported in clinical trials and postmarketing surveillance.1,b
bPatients with Glanzmann’s thrombasthenia (N=140) received NovoSeven® RT for 518 bleeding episodes, surgeries, or traumatic injuries. The following adverse reactions were reported: deep vein thrombosis (n=1), headache (n=2), fever (n=2), nausea (n=1), and dyspnea (n=1).1
NovoSeven® RT provides effective bleed control for your patients with GT with refractoriness to platelet transfusions1
Platelet transfusions may be given when conservative and local measures are insufficient but may also lead to the development of antibodies to platelets or clinical refractoriness.3 Implementing NovoSeven® RT as a go-to treatment supports the management of nonsurgical and surgical bleeds in the presence of platelet antibodies.1
Mechanism of Action (MOA)1
NovoSeven® RT is a bypassing agent that activates clotting factors directly at the bleed site to stop bleeding; does not rely on platelets
Usage in GT1
FDA approved for treatment of bleeding episodes and perioperative management in adults and children with GT with refractoriness to platelet transfusions, with or without antibodies to platelets
Route of administration1
Intravenous
Not intended to be a comparison of efficacy or safety.
MOA: Replaces missing platelets with donor platelets
Usage in GT: For patients with GT without refractoriness to platelet transfusions and/or antibodies to platelets
Route of administration: Intravenous
MOA: Slows down the mechanisms related to the breakdown of clots
Usage in GT: Can be useful for: bleeding after surgeries, certain bleeding disorders, pregnancy complications, liver disease, some cancers
Route of administration: Oral or intravenous
MOA: Slows down the mechanisms related to the breakdown of clots
Usage in GT: Reduces heavy menstrual bleeding or is used short-term to control bleeding during tooth extractions
Route of administration: Oral or intravenous
MOA: Helps stop minor bleeding by facilitating the blood clotting process
Usage in GT: Used on skin when: there are minor bleeds or oozes, or when stitches or cauterization do not help stop bleeds
Route of administration: Topical
MOA: Can thin the uterine lining so menstrual bleeding may be lighter
Usage in GT: Reducing menstrual bleeding, regulating menstrual cycles, and preventing pregnancy
Route of administration: Oral, intrauterine device (IUD), arm implant, and hormone injection
MOA: Slows blood flow, reduces inflammation, and eases pain
Usage in GT: Used to help ease pain and decrease swelling associated with joint bleeds in people with bleeding disorders
Route of administration: Topical
MOA: Applies pressure to help stop nasal bleeding
Usage in GT: May help to treat nosebleeds
Route of administration: Nasal
MOA: Seals bleeding vessels through heat application
Usage in GT: May help to treat nosebleeds and removal of abnormal or damaged tissue
Route of administration: Nasal
MOA: Constricts nasal blood vessels to slow bleeding
Usage in FVIId: May help to treat nosebleeds
Route of administration: Nasal
Learn more about diagnosing Glanzmann’s thrombasthenia.
Because GT shares symptoms with other bleeding disorders, diagnosis can be difficult, especially in emergent situations.9,20 This diagnostic algorithm may help.c
cThe provided example is for discussion purposes only and is not intended to represent a recommended algorithm for actual decision-making. This example is for illustrative purposes and does not constitute guidance for medical advice or treatment.
Learn more about diagnosing Glanzmann’s thrombasthenia.
Because GT shares symptoms with other bleeding disorders, diagnosis can be difficult, especially in emergent situations.3,4 This diagnostic algorithm may help.a
aThe provided example is for discussion purposes only and is not intended to represent a recommended algorithm for actual decision making. This example is for illustrative purposes and does not constitute guidance for medical advice or treatment.
Study design
Patients considered: Data were collected from the GTR in patients with Glanzmann’s thrombasthenia (N=218).
Study design: Adjudicator-assessed effectiveness of treatment regimens in patients with GT (N=218) in all severe bleeding episodes and all surgical procedures (N=1073) based on review of Glanzmann’s Thrombasthenia Registry (GTR) data unblinded to investigator-coded efficacy. Efficacy was evaluated on a 2-point scale (clinical assessment of success or failure of treatment regimen as a whole, blinded and unblinded to investigator-coded outcome) including 92 patients treated with NovoSeven® RT for 266 bleeding episodes and 77 patients treated for 160 surgical procedures.
Find the dose for your patients with GTd
dAs a reminder, for US health care professionals only.
Discover educational materials
Treating GT brochure: a resource for you and your patients
Important Safety Information for NovoSeven® RT
WARNING: THROMBOSIS
- Serious arterial and venous thrombotic events following administration of NovoSeven® RT have been reported
- Discuss the risks and explain the signs and symptoms of thrombotic and thromboembolic events to patients who will receive NovoSeven® RT
- Monitor patients for signs or symptoms of activation of the coagulation system and for thrombosis
Warnings and Precautions
- Serious arterial and venous thrombotic events have been reported in clinical trials and postmarketing surveillance
- Patients with congenital hemophilia receiving concomitant treatment with aPCCs (activated prothrombin complex concentrates), older patients particularly with acquired hemophilia and receiving other hemostatic agents, and patients with a history of cardiac and vascular disease may have an increased risk of developing thrombotic events
- Hypersensitivity reactions, including anaphylaxis, can occur with NovoSeven® RT. Patients with a known hypersensitivity to mouse, hamster, or bovine proteins may be at a higher risk of hypersensitivity reactions. Discontinue infusion and administer appropriate treatment when hypersensitivity reactions occur
- Factor VII deficient patients should be monitored for prothrombin time (PT) and factor VII coagulant activity (FVII:C). If FVII:C fails to reach the expected level, or PT is not corrected, or bleeding is not controlled after treatment with the recommended doses, antibody formation may be suspected and analysis for antibodies should be performed
- Laboratory coagulation parameters (PT/INR, aPTT, FVII:C) have shown no direct correlation to achieving hemostasis
Adverse Reactions
- The most common and serious adverse reactions in clinical trials are thrombotic events. Thrombotic adverse reactions following the administration of NovoSeven® RT in clinical trials occurred in 4% of patients with acquired hemophilia and 0.2% of bleeding episodes in patients with congenital hemophilia
Drug Interactions
- Thrombosis may occur if NovoSeven® RT is administered concomitantly with Coagulation Factor XIII
Please click here for NovoSeven® RT Prescribing Information, including Boxed Warning.
Indications and Usage
NovoSeven® RT (coagulation Factor VIIa, recombinant) is a coagulation factor indicated for:
- Treatment of bleeding episodes and perioperative management in adults and children with hemophilia A or B with inhibitors, congenital Factor VII (FVII) deficiency, and Glanzmann’s thrombasthenia with refractoriness to platelet transfusions, with or without antibodies to platelets
- Treatment of bleeding episodes and perioperative management in adults with acquired hemophilia
Important Safety Information for NovoSeven® RT
WARNING: THROMBOSIS
- Serious arterial and venous thrombotic events following administration of NovoSeven® RT have been reported
- Discuss the risks and explain the signs and symptoms of thrombotic and thromboembolic events to patients who will receive NovoSeven® RT
- Monitor patients for signs or symptoms of activation of the coagulation system and for thrombosis
Important Safety Information for NovoSeven® RT
WARNING: THROMBOSIS
- Serious arterial and venous thrombotic events following administration of NovoSeven® RT have been reported
- Discuss the risks and explain the signs and symptoms of thrombotic and thromboembolic events to patients who will receive NovoSeven® RT
- Monitor patients for signs or symptoms of activation of the coagulation system and for thrombosis
Warnings and Precautions
- Serious arterial and venous thrombotic events have been reported in clinical trials and postmarketing surveillance
- Patients with congenital hemophilia receiving concomitant treatment with aPCCs (activated prothrombin complex concentrates), older patients particularly with acquired hemophilia and receiving other hemostatic agents, and patients with a history of cardiac and vascular disease may have an increased risk of developing thrombotic events
- Hypersensitivity reactions, including anaphylaxis, can occur with NovoSeven® RT. Patients with a known hypersensitivity to mouse, hamster, or bovine proteins may be at a higher risk of hypersensitivity reactions. Discontinue infusion and administer appropriate treatment when hypersensitivity reactions occur
- Factor VII deficient patients should be monitored for prothrombin time (PT) and factor VII coagulant activity (FVII:C). If FVII:C fails to reach the expected level, or PT is not corrected, or bleeding is not controlled after treatment with the recommended doses, antibody formation may be suspected and analysis for antibodies should be performed
- Laboratory coagulation parameters (PT/INR, aPTT, FVII:C) have shown no direct correlation to achieving hemostasis
Adverse Reactions
- The most common and serious adverse reactions in clinical trials are thrombotic events. Thrombotic adverse reactions following the administration of NovoSeven® RT in clinical trials occurred in 4% of patients with acquired hemophilia and 0.2% of bleeding episodes in patients with congenital hemophilia
Drug Interactions
- Thrombosis may occur if NovoSeven® RT is administered concomitantly with Coagulation Factor XIII
Please click here for NovoSeven® RT Prescribing Information, including Boxed Warning.
Indications and Usage
NovoSeven® RT (coagulation Factor VIIa, recombinant) is a coagulation factor indicated for:
- Treatment of bleeding episodes and perioperative management in adults and children with hemophilia A or B with inhibitors, congenital Factor VII (FVII) deficiency, and Glanzmann’s thrombasthenia with refractoriness to platelet transfusions, with or without antibodies to platelets
- Treatment of bleeding episodes and perioperative management in adults with acquired hemophilia
References
- NovoSeven RT [package insert]. Plainsboro, NJ: Novo Nordisk Inc.
- National Hemophilia Foundation. MASAC recommendation on administration of inhibitor bypassing agents in the home for patients with hemophilia and inhibitors (MASAC Document #233.) June 4, 2015. Accessed July 8, 2026. https://www.bleeding.org/sites/default/files/document/files/233homeadministration.pdf
- Cleveland Clinic. Glanzmann thrombasthenia. Cleveland Clinic. Updated April 30, 2024. Accessed September 30, 2025. https://my.clevelandclinic.org/health/diseases/glanzmann-thrombasthenia
- Krause KA, Graham BC. Glanzmann thrombasthenia. In: StatPearls. StatPearls Publishing; 2023. Accessed November 7, 2025. https://www.ncbi.nlm.nih.gov/books/NBK538270/
- Nurden AT, George JN. Inherited abnormalities of the platelet membrane: Glanzmann thrombasthenia, Bernard-Soulier syndrome, and other disorders. In: Colman RW, Clowes AW, Goldhaber SZ, Marder VJ, George JN, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 5th ed. Lippincott Williams & Wilkins; 2006:1-43.
- George JN. Platelets. Lancet. 2000;355(9214):1531-1539.
- Amicar. Package insert. Hospira, Inc; 2018.
- Kaseer H, Sanghavi DK. Aminocaproic acid. In: StatPearls. StatPearls Publishing; 2023. Accessed November 7, 2025. https://www.ncbi.nlm.nih.gov/books/NBK554475/
- Solh T, Botsford A, Solh M. Glanzmann’s thrombasthenia: pathogenesis, diagnosis, and current and emerging treatment options. J Blood Med. 2015;6:219-227.
- Cyklokapron. Package insert. Pfizer Inc; 2026.
- Lysteda. Package insert. Ferring Pharmaceuticals Inc; 2020.
- Thrombin-JMI. Package insert. Pfizer Inc; 2026.
- Lethaby A, Wise MR, Weterings MA, Bofill Rodriguez M, Brown J. Combined hormonal contraceptives for heavy menstrual bleeding. Cochrane Database Syst Rev. 2019;2(2):CD000154.
- Cleveland Clinic. Birth control pills. Cleveland Clinic. Updated July 5, 2023. Accessed October 7, 2025. https://my.clevelandclinic.org/health/treatments/3977-birth-control-the-pill
- Cleveland Clinic. RICE method for injury. Cleveland Clinic. Updated January 24, 2025. Accessed November 10, 2025. https://my.clevelandclinic.org/health/treatments/rice-method
- Cleveland Clinic. Nosebleed (Epistaxis). Cleveland Clinic. Published December 18, 2024. Accessed September 30, 2025. https://my.clevelandclinic.org/health/diseases/13464-nosebleed-epistaxis
- Leadon M, Hohman MH. Posterior epistaxis nasal pack. In: StatPearls. StatPearls Publishing; 2023. Accessed November 7, 2025. https://www.ncbi.nlm.nih.gov/books/NBK576436/
- Cleveland Clinic. Electrocauterization. Cleveland Clinic. Updated August 15, 2022. Accessed September 30, 2025. https://my.clevelandclinic.org/health/treatments/24032-electrocauterization
- Smith J, Hanson J, Chowdhury R, Bungard TJ. Community-based management of epistaxis: who bloody knows? Can Pharm J (Ott). 2019;152(3):164-176.
- Lambert MP. What to do when you suspect an inherited platelet disorder. Hematology Am Soc Hematol Educ Program. 2011;2011:377-383.